REFRACTORY NEUROBLASTOMA
Clinical trials for REFRACTORY NEUROBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY NEUROBLASTOMA trials appear
Sign up with your email to follow new studies for REFRACTORY NEUROBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on childhood cancer in new trial
Disease control Recruiting nowThis study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on neuroblastoma cells. It is for children and young adults aged 1 to 21 whose cancer has come back or not responded to standard treatments. Participants first receive ch…
Matched conditions: REFRACTORY NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 17, 2026 03:56 UTC
-
Engineered immune cells take on childhood cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called GPC2 CAR T cells for children with advanced neuroblastoma or retinoblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and at…
Matched conditions: REFRACTORY NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Engineered immune cells take aim at childhood cancer in new trial
Disease control Recruiting nowThis study tests a new treatment for children and young adults with high-risk neuroblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein called ALK found o…
Matched conditions: REFRACTORY NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Roberto Chiarle • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for kids with Hard-to-Treat cancers: Two-Drug attack on tumors
Disease control Recruiting nowThis study is for children and young adults whose solid tumors have come back or not gone away. It tests two different drug pairs that damage cancer cell DNA to kill the tumor. The goal is to find the best dose and see if the treatment can shrink or stop the cancer.
Matched conditions: REFRACTORY NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for kids with tough cancers: experimental drug PEEL-224 enters trials
Disease control Recruiting nowThis study tests a new drug called PEEL-224, alone or with standard chemotherapy, in children and young adults whose solid tumors have not responded to treatment or have returned. The first part finds the safest dose, and the second part measures how well the drug combination shr…
Matched conditions: REFRACTORY NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Theodore Laetsch • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Engineered immune cells take aim at stubborn childhood cancer
Disease control Recruiting nowThis early-phase trial tests a new treatment for children with neuroblastoma that has come back or is hard to treat. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells carrying a protein called PHOX2B. The main goal is to find a safe do…
Matched conditions: REFRACTORY NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Immune cell combo offers new hope for kids with resistant cancers
Disease control Recruiting nowThis study is for children with neuroblastoma or osteosarcoma that has come back or not responded to treatment. It tests a new approach: giving donor immune cells (gamma delta T cells) along with standard chemotherapy and an antibody drug. The main goal is to find the safest dose…
Matched conditions: REFRACTORY NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 06, 2026 16:01 UTC